University of Toronto and Medicxi launch Janpix Inc. with US $19M in funding to advance Dual Impact Cancer Therapies

University of Toronto and Medicxi launch Janpix Inc. with US $19M in funding to advance Dual Impact Cancer Therapies

Janpix Inc., a privately held biopharmaceutical company dedicated to the discovery and development of inhibitors targeted to Signal Transducer & Activator of Transcription (STAT) proteins, announced today that it has closed a US $19M investment round led by Medicxi, a GSK and J&J backed venture fund, which initially seeded the company.